CVM Stock - CEL-SCI Corp.

CVM Stock Chart

CVM Profile

CEL-SCI Corporation operates as a clinical-stage biotechnology firm focused on pioneering immune-based therapies for cancer and infectious diseases. The company is at the forefront of research, development, and manufacturing of innovative treatments designed to harness the immune system's capabilities. Central to its pipeline is Multikine, a Leukocyte Interleukin injection, which has successfully concluded a pivotal Phase 3 clinical trial targeting locally advanced primary squamous cell carcinoma of the head and neck.

In addition to Multikine, CEL-SCI is advancing the Ligand Epitope Antigen Presentation System (LEAPS) technology. This proprietary T-cell modulation platform is in pre-clinical stages and holds promise for stimulating the human immune response against a spectrum of conditions including bacterial, viral, and parasitic infections. Moreover, LEAPS technology is being explored for its potential in addressing autoimmune diseases, allergies, transplantation rejections, and various cancers.

CEL-SCI's commitment to innovation extends to its development of CEL-2000 and CEL-4000 product candidates. These therapies are targeted treatments for rheumatoid arthritis, reflecting the company's broad therapeutic approach and dedication to meeting critical medical needs.

Founded in 1983 and headquartered in Vienna, Virginia, CEL-SCI Corporation continues to drive advancements in immunotherapy. With a focus on leveraging cutting-edge science to improve patient outcomes, the company remains poised to make significant strides in the biotechnology and healthcare sectors globally.

CVM Revenue Chart

CVM Earnings

Analyst Ratings